Literature DB >> 32427297

Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans.

James D Chambers1, Rachel C Lai1, Nikoletta M Margaretos1, Ari D Panzer1, Joshua T Cohen1, Peter J Neumann1.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32427297      PMCID： PMC7237961          DOI： 10.1001/jama.2020.2229

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  3 in total

1.  Specialty Drug Coverage Varies Across Commercial Health Plans In The US.

Authors:  James D Chambers; David D Kim; Elle F Pope; Jennifer S Graff; Colby L Wilkinson; Peter J Neumann
Journal:  Health Aff (Millwood)       Date:  2018-07       Impact factor: 6.301

2.  Why Are Biosimilars Not Living up to Their Promise in the US?

Authors:  Mike Z Zhai; Ameet Sarpatwari; Aaron S Kesselheim
Journal:  AMA J Ethics       Date:  2019-08-01

Review 3.  Prescription drug cost sharing: associations with medication and medical utilization and spending and health.

Authors:  Dana P Goldman; Geoffrey F Joyce; Yuhui Zheng
Journal:  JAMA       Date:  2007-07-04       Impact factor: 56.272
  3 in total
  2 in total

Review 1.  Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review.

Authors:  Akshitha Thatiparthi; Amylee Martin; Jeffrey Liu; Alexander Egeberg; Jashin J Wu
Journal:  Am J Clin Dermatol       Date:  2021-04-16       Impact factor: 7.403

2.  Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians.

Authors:  Jingyan Yang; Kelly Blinzler; Joshua Lankin; Sapna Vijayakumar; Martine C Maculaitis; Ahmed Shelbaya
Journal:  BioDrugs       Date:  2021-11-25       Impact factor: 5.807
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.